TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on...
TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on...
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates PR Newswire CRANFORD, N.J., July 10, 2024 Multiple catalysts for potentially transformative assets in second half of...
New York, NY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) (the “Company”), announced today that if the proposal to amend the Company’s Amended and...
Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction...
New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today announced that, in order to extend the date by which the Company must complete its...
New York, NY, July 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today announced that, in order to extend the date by which the Company must complete its...
New York, NY, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (Nasdaq: TENKU), a newly incorporated blank check company, today announced that, commencing on December 8...
New York, Oct. 18, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU) (the “Company”), a newly incorporated blank check company incorporated as a Cayman Islands exempted company...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約